Latest News about BMRN
Recent news which mentions BMRN
Why Is BioMarin Stock Trading Higher On Thursday?
February 20, 2025
From Benzinga
Earnings Scheduled For February 19, 2025
February 19, 2025
From Benzinga
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
From Benzinga
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
From Benzinga
From Benzinga
10 Magnificent Stocks That Can Make You Richer in 2025
January 03, 2025
From Motley Fool
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
November 15, 2024
Tickers
BMRN
From Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
November 06, 2024
Tickers
BMRN
From Benzinga
CAMP4 Analyst Highlights Rare Disease Platform Potential
November 05, 2024
From Benzinga
From Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
October 28, 2024
Tickers
BMRN
From Benzinga
How Is The Market Feeling About Biomarin Pharmaceutical?
October 15, 2024
Tickers
BMRN
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
October 04, 2024
Tickers
BMRN
From Benzinga
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
September 25, 2024
From Benzinga
From Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
From Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
From Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
September 16, 2024
From Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
September 10, 2024
Tickers
BMRN
From Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
From Benzinga
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
September 05, 2024
From Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
From Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
August 21, 2024
Tickers
BMRN
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.